Elan announces first Japanese approval of NanoCrystal technology product
The Japanese Ministry of Health, Labour and Welfare has approved Elan Drug Technologies" use of NanoCrystal technology in EMEND (aprepitant), for the treatment of nausea and vomiting caused by cancer chemotherapy.
The Japanese Ministry of Health, Labour and Welfare has approved Elan Drug Technologies" use of NanoCrystal technology in EMEND (aprepitant), for the treatment of nausea and vomiting caused by cancer chemotherapy.
EMEND, which was developed by a subsidiary of Merck & Co and licensed to Ono Pharmaceuticals for the Japanese market, is the first licensed product approved in Japan that incorporates Elan Drug Technologies" NanoCrystal technology.
The company says its NanoCrystal technology enables formulation of poorly water soluble compounds for all routes of administration. This technology eliminates the need for EMEND to be taken with food and improves bioavailability by 600%.
"We hope this is the first of many products using our NanoCrystal technology to be launched in Japan," said Shane Cooke, executive vice president and head of Elan Drug Technologies.
Five licensed products have now been approved using the NanoCrystal technology by various health authorities including the US Food and Drug Administration (FDA).
